WeVote
Log In

Bill

Bill

S 6164

Relates to prescription drugs in Medicaid managed care programs; repealer

2025 Regular Session Introduced by James Skoufis

Repeals statutes governing prescription drugs in Medicaid managed care, reshaping coverage for beneficiaries, plans, pharmacies, and state agencies.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · S 6164

Summary of Bill S 6164

Overview and purpose

  • Bill Number: S 6164
  • Title: Relates to prescription drugs in Medicaid managed care programs; repealer
  • Purpose (as indicated by the title): The bill appears to repeal existing statutes related to prescription drugs within Medicaid managed care programs. The exact scope and details of what would be repealed are contained in the bill’s text, which would define the specific provisions affected and any transitional provisions.
  • Primary sponsor: James Skoufis
  • Status (as introduced): Referred to the Senate Health Committee on March 6, 2025

Key provisions (what the bill would change)

  • Repealer: The core action is the repeal of certain statutory provisions governing prescription drugs in Medicaid managed care programs. Because the bill is described as a repealer, it would remove existing requirements or rules currently in law related to how prescription drugs are managed, covered, or administered within Medicaid managed care.
  • Scope and specifics: The exact provisions to be repealed, any interim or transitional rules, and any subsequent regulatory or administrative changes would be found in the bill’s text and any accompanying notes. The available information does not specify which statutes are targeted or what would replace them, if anything.

Who would be affected

  • Medicaid managed care programs and plans operating within the state
  • Prescription drug coverage and administration within Medicaid managed care
  • Medicaid beneficiaries enrolled in managed care, as well as participating pharmacies and providers
  • State agencies administering Medicaid managed care and drug benefit policies

Procedural and timeline aspects

  • Introduction: March 6, 2025
  • Current status: Referred to the Health Committee (mass-evidence shows two identical entries for “REFERRED TO HEALTH” on the same date, indicating formal committee referral)
  • Next steps (generally in the New York Senate process): If advanced, the bill would move through committee discussion and potential amendments, receive a floor vote in the Senate, pass to the Assembly (or companion measures), and must be enacted by both houses and signed by the governor to become law. Any amendments or changes could affect the final scope of the repealer.

Context and related legislation

  • Related bills from prior sessions (suggesting ongoing policy interest in prescription drugs in Medicaid managed care): S 1532, S 7894, S 2919, S 1175, S 5009, S 7051
  • These related bills may provide background on the policy debates and issues the sponsor or sponsors have previously pursued.

Notes: This summary reflects publicly available information as of the introduced date. For detailed text, exact repeal targets, and potential fiscal or regulatory impacts, review the bill’s full language and any fiscal notes or sponsor memos when they become available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.